Syncona Shs GBP (GB:SYNC) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top StocksMake ...

Oct. 31, 2024 — A research team has found that giving iron supplements to children living with human immunodeficiency virus (HIV) in sub-Saharan Africa could be an ... Kidney Transplantation ...

"Slingshot represents an opportunity to bridge the gap between academic innovation and clinical development of a novel ...

Syncona has launched Slingshot Therapeutics with an initial $15 million investment through its Syncona Accelerator initiative ...

Syncona said the performance was mostly driven by a decline in Autolus Therapeutics PLC share price and a weaker US dollar, and was partially offset by valuation uplifts from private portfolio company ...

Syncona Ltd, (“Syncona”) a leading life science investor focused on creating, building and scaling global leaders in life science, today announces that it has launched a new portfolio company ...

London-based life science investor Syncona today announced its interim results for the six months ending 30 September 2024.

(Alliance News) - Syncona Ltd announced on Monday that the US Food & Drug Administration has granted marketing approval to one of its portfolio companies for a new product. The life science investor ...

Syncona noted that the approval is set against the backdrop of poor outcomes for patients with r/r B-ALL, an aggressive blood ...

Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...

London open The FTSE 100 is expected to open 45 points higher on Monday, having closed down 0.84% on Friday at 8,072.39.

Syncona Shs GBP (GB:SYNC) has released an update. Syncona’s portfolio company, Autolus Therapeutics, has received FDA ...